title: Approvals in 2016: cost-benefit challenges of new anticancer agents.
authors.affiliation: Department of Medical Oncology, Brighton and Sussex University Hospitals, Eastern Road, Brighton BN2 5BE, UK.
authors.forename: Philip
authors.initials: P
authors.lastname: Savage
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D019086:Bridged Bicyclo Compounds, Heterocyclic / Q000191:economics / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D017277:Drug Approval; D016527:Drug Costs / Q000706:statistics & numerical data* / Q000639:trends; D006801:Humans; D007211:Indoles / Q000191:economics / Q000627:therapeutic use; D013449:Sulfonamides / Q000191:economics / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D019086:Bridged Bicyclo Compounds, Heterocyclic; D007211:Indoles; D013449:Sulfonamides; C000594389:atezolizumab; C531549:rucaparib; C579720:venetoclax; C000589393:olaratumab